Figure 5. The BIM deletion polymorphism can confer EGFR-mutant NSCLC cells resistance to erlotinib than that without BIM deletion counterparts.

(A) The cell cycle distribution for EGFR-mutant NSCLC cells by PI staining. (B–D). NSCLC cells expressing EGFR-mutant and harboring the BIM deletion polymorphism had less apoptotic cell ratio. Erlotinib-resistant cells with BIM polymorphism had less caspase-3 activity (B), less DNA fragmentation(C) and less Annexin V+ cell populations(D) than their non-BIM deletion counterparts.